Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,019 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Combined effect of obesity and diabetes on early breast cancer outcome: a prospective observational study.
Buono G, Crispo A, Giuliano M, De Angelis C, Schettini F, Forestieri V, Lauria R, Pensabene M, De Laurentiis M, Augustin LSA, Amore A, D'Aiuto M, Tortoriello R, Accurso A, Cavalcanti E, Botti G, Montella M, De Placido S, Arpino G. Buono G, et al. Among authors: de angelis c, de placido s, de laurentiis m. Oncotarget. 2017 Dec 5;8(70):115709-115717. doi: 10.18632/oncotarget.22977. eCollection 2017 Dec 29. Oncotarget. 2017. PMID: 29383194 Free PMC article.
Metabolic syndrome and early stage breast cancer outcome: results from a prospective observational study.
Buono G, Crispo A, Giuliano M, De Angelis C, Schettini F, Forestieri V, Lauria R, De Laurentiis M, De Placido P, Rea CG, Pacilio C, Esposito E, Grimaldi M, Nocerino F, Porciello G, Giudice A, Amore A, Minopoli A, Botti G, De Placido S, Trivedi MV, Arpino G. Buono G, et al. Among authors: de angelis c, de placido s, de placido p, de laurentiis m. Breast Cancer Res Treat. 2020 Jul;182(2):401-409. doi: 10.1007/s10549-020-05701-7. Epub 2020 Jun 4. Breast Cancer Res Treat. 2020. PMID: 32500397 Free PMC article.
Multi-gene panel testing increases germline predisposing mutations' detection in a cohort of breast/ovarian cancer patients from Southern Italy.
Nunziato M, Di Maggio F, Pensabene M, Esposito MV, Starnone F, De Angelis C, Calabrese A, D'Aiuto M, Botti G, De Placido S, D'Argenio V, Salvatore F. Nunziato M, et al. Among authors: de angelis c, de placido s. Front Med (Lausanne). 2022 Aug 11;9:894358. doi: 10.3389/fmed.2022.894358. eCollection 2022. Front Med (Lausanne). 2022. PMID: 36035419 Free PMC article.
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.
De Placido S, Gallo C, De Laurentiis M, Bisagni G, Arpino G, Sarobba MG, Riccardi F, Russo A, Del Mastro L, Cogoni AA, Cognetti F, Gori S, Foglietta J, Frassoldati A, Amoroso D, Laudadio L, Moscetti L, Montemurro F, Verusio C, Bernardo A, Lorusso V, Gravina A, Moretti G, Lauria R, Lai A, Mocerino C, Rizzo S, Nuzzo F, Carlini P, Perrone F; GIM Investigators. De Placido S, et al. Lancet Oncol. 2018 Apr;19(4):474-485. doi: 10.1016/S1470-2045(18)30116-5. Epub 2018 Feb 23. Lancet Oncol. 2018. PMID: 29482983 Clinical Trial.
Prognostic Relevance of Progesterone Receptor Levels in Early Luminal-Like HER2 Negative Breast Cancer Subtypes: A Retrospective Analysis.
Diana A, Carlino F, Buono G, Antoniol G, Famiglietti V, De Angelis C, Carrano S, Piccolo A, De Vita F, Ciardiello F, Daniele B, Arpino G, Orditura M. Diana A, et al. Among authors: de angelis c, de vita f. Front Oncol. 2022 Mar 28;12:813462. doi: 10.3389/fonc.2022.813462. eCollection 2022. Front Oncol. 2022. PMID: 35419293 Free PMC article.
Towards personalized treatment for early stage HER2-positive breast cancer.
Goutsouliak K, Veeraraghavan J, Sethunath V, De Angelis C, Osborne CK, Rimawi MF, Schiff R. Goutsouliak K, et al. Among authors: de angelis c. Nat Rev Clin Oncol. 2020 Apr;17(4):233-250. doi: 10.1038/s41571-019-0299-9. Epub 2019 Dec 13. Nat Rev Clin Oncol. 2020. PMID: 31836877 Free PMC article. Review.
Safety and immunogenicity of the COVID-19 vaccine BNT162b2 for patients with breast and gynecological cancer on active anticancer therapy: Results of a prospective observational study.
De Placido P, Pietroluongo E, De Angelis C, Tafuro M, Barraco C, Giannatiempo R, Buonaiuto R, Schettini F, Iervolino A, Vozzella EA, Giuliano M, Bianco R, Arpino G. De Placido P, et al. Among authors: de angelis c. Front Oncol. 2022 Aug 19;12:951026. doi: 10.3389/fonc.2022.951026. eCollection 2022. Front Oncol. 2022. PMID: 36059663 Free PMC article.
PARP Inhibitors for Breast Cancer Treatment: A Review.
Morganti S, Marra A, De Angelis C, Toss A, Licata L, Giugliano F, Taurelli Salimbeni B, Berton Giachetti PPM, Esposito A, Giordano A, Bianchini G, Garber JE, Curigliano G, Lynce F, Criscitiello C. Morganti S, et al. Among authors: de angelis c. JAMA Oncol. 2024 Mar 21. doi: 10.1001/jamaoncol.2023.7322. Online ahead of print. JAMA Oncol. 2024. PMID: 38512229
Case Report: Detection of a Novel Germline PALB2 Deletion in a Young Woman With Hereditary Breast Cancer: When the Patient's Phenotype History Doesn't Lie.
De Angelis C, Nardelli C, Concolino P, Pagliuca M, Setaro M, De Paolis E, De Placido P, Forestieri V, Scaglione GL, Ranieri A, Lombardo B, Pastore L, De Placido S, Capoluongo E. De Angelis C, et al. Among authors: de placido s, de paolis e, de placido p. Front Oncol. 2021 Feb 24;11:602523. doi: 10.3389/fonc.2021.602523. eCollection 2021. Front Oncol. 2021. PMID: 33718150 Free PMC article.
1,019 results